RRML - Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2016): 55%

Română English


SCImago Journal & Country Rank


Advanced search


Top 10 downloaded articles
- September 2018 -
 
Rationale and Design of a Pros... 12
Biomarkers in heart failure: f... 11
Romanian Review of Laboratory ... 9
Postoperative interleukin-8 le... 8
Serum hs-CRP, YKL-40 and brain... 6
Biomarkers in Obesity... 6
Phenotypic and molecular ident... 5
Plasma phosphorylated neurofil... 4
Antibiotic susceptibility and ... 4
Candida albicans isolates from... 4

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 25(4)/2017 DOI:10.1515/rrlm-2017-0030
XML
TXT

Research article

Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals

Maria Nițescu, Cristina Vâjâitu, Oana Săndulescu, Adrian Streinu-Cercel, Daniela Pițigoi, Liliana Lucia Preoțescu, Anca Streinu-Cercel

Correspondence should be addressed to: Oana Săndulescu

Abstract:

Introduction. The past years have revolutionized the treatment of hepatitis C virus (HCV) infection, with high rates of sustained virologic response (SVR). Furthermore, liver fibrosis has recently been redefined as a dynamic, reversible process. Methods. We performed a prospective cohort study to assess the role of laboratory evaluations and non-invasive measurement of liver stiffness in establishing the right time for starting treatment and in assessing the regression of liver fibrosis in Romanian patients treated with direct acting antivirals (DAA) for genotype 1b chronic hepatitis C. Results. We present the results for 102 patients, with a mean age of 58.5 years, and a rate of SVR of 100%. Our study has ruled out older age (p=0.628), IL28B non-CC genotype (p=0.693), baseline viral load above the cutoff of 600,000 IU/mL (p=0.353), and the presence of diabetes mellitus (p=0.272) or baseline steatosis (p=0.706) as factors potentially influencing the regression of liver fibrosis following DAA treatment of HCV infection with the 3D regimen. The quantitative regression of liver stiffness was inversely correlated with the duration of HCV infection (p=0.017), suggesting that timely treatment might associate better outcomes in terms of liver fibrosis. Conclusion. Our study’s results point towards the need to start DAA treatment earlier in patients with HCV infection.

Keywords: liver fibrosis, HCV, DAA, SVR, prognostic laboratory markers

Received: 12.6.2017
Accepted: 21.8.2017
Published: 1.9.2017

 
  PDF Download full text PDF
(578 KB)
     
 
How to cite
Nițescu M, Vâjâitu C, Săndulescu O, Streinu-Cercel A, Pițigoi D, Preoțescu LL, et al. Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals. Rev Romana Med Lab. 2017;25(4):355-63. DOI:10.1515/rrlm-2017-0030